Calendario de promoción Adynxx Inc
Horario avanzado
gráfico sencillo
Acerca de la empresa
Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.
| ISIN |
US00784D1037 |
| Industry |
Biotechnology |
| Sector |
Health Care |
| Валюта |
usd |
| Валюта отчета |
usd |
| Сайт |
https://www.adynxx.com
|
| Цена ао |
0.0001 |
| Cambio de precio por día: |
0% (0.0001) |
| Cambio de precio por semana.: |
0% (0.0001) |
| Cambio de precio por mes: |
0% (0.0001) |
| Cambio de precio en 3 meses.: |
0% (0.0001) |
| Cambio de precio en seis meses: |
0% (0.0001) |
| Cambio de precio por año: |
0% (0.0001) |
| Cambio de precio en 3 años.: |
-99.96% (0.2485) |
| Cambio de precio en 5 años.: |
-100% (2.32) |
| Cambio de precio en 10 años.: |
0% (0.0001) |
| Cambio de precio desde principios de año.: |
0% (0.0001) |
|
|
Subestimación
| Nombre |
Significado |
Calificación |
| P/S |
0 |
0 |
| P/BV |
0 |
0 |
| P/E |
0 |
0 |
| EV/EBITDA |
0 |
0 |
| Total: |
|
2.5 |
|
Eficiencia
| Nombre |
Significado |
Calificación |
| ROA, % |
0 |
0 |
| ROE, % |
0 |
0 |
| Total: |
|
0 |
|
|
|
Dividendos
| Nombre |
Significado |
Calificación |
| Div yield, % |
0 |
0 |
| DSI |
1 |
10 |
| Total: |
|
3.06 |
|
Deber
| Nombre |
Significado |
Calificación |
| Debt/EBITDA |
0 |
10 |
| Total: |
|
10 |
|
Impulso de crecimiento
| Nombre |
Significado |
Calificación |
| Rentabilidad Revenue, % |
-53.7 |
0 |
| Rentabilidad Ebitda, % |
-93.16 |
0 |
| Rentabilidad EPS, % |
-95.64 |
0 |
| Total: |
|
0 |
|
| Supervisor |
Título profesional |
Pago |
año de nacimiento |
| Mr. Richard Orr Esq., J.D. |
President, CEO, Principal Financial Officer & Director |
|
1961 (63 año) |
| Dr. Julien Mamet Ph.D. |
Founder, Chief Scientific Officer & Director |
|
1976 (48 años) |
| Mr. William Martin |
Executive Vice President of Corporate Development & Operations |
|
|
| Ms. Dina Gonzalez |
Principal Accounting Officer & Senior VP of Finance |
|
|
| Ms. Kimberley Hebert |
Senior Director of Clinical Operations |
|
|
